Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) is thrilled to invite you to join its conference call on March 2, 2023 at 2:00 pm CET (8:00 am ET) to discuss the full year results of 2022. As a biotechnology company focused on the discovery and development of innovative peptide-based medicines, Zealand Pharma A/S is sure to have some exciting news to share! Don’t miss out on this unique opportunity to hear firsthand about the company’s progress and future prospects.
Join us for an exciting call with President and Chief Executive Officer, Adam Steensberg, Chief Financial Officer, Henriette Wennicke, and Chief Medical Officer, David Kendall. During the call, they will provide an informative presentation, followed by a Q&A session, all in English. Don’t miss out on this great opportunity to gain insight into the inner workings of the company.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is an innovative biotechnology company that is revolutionizing the way we treat diseases. With more than 10 drug candidates in clinical development, two of which have already reached the market, Zealand is well on its way to becoming a leader in peptide-based medicines. The company has also established strong partnerships with top pharmaceutical companies, providing them with access to its cutting-edge products. With its promise of better health outcomes, Zealand is making strides in redefining the future of medicine.
NewZealand, founded in 1998 and headquartered in Copenhagen, Denmark, has made impressive strides in the global market, with a presence that now stretches from Copenhagen to Boston in the United States. With a reputation for innovation and excellence, NewZealand is a leader in the industry.